Accord BioPharma Launches FILKRI Biosimilar in U.S. Market
What happened
Accord BioPharma announced the U.S. commercial launch of FILKRI (filgrastim-laha) on October 12, 2026. FILKRI is a biosimilar to Neupogen (filgrastim) and received FDA approval in January 2026. The drug is indicated for various oncology supportive care uses, including decreasing infection incidence in patients receiving myelosuppressive anti-cancer drugs. The drug is available with a permanent Q-code to standardize billing and reimbursement across care sites.
From prnewswire.com
Why it matters
The launch expands patient access to therapies in the United States. As a biosimilar, FILKRI introduces a competing therapy into the oncology supportive care market. Accord BioPharma stated this launch furthers its goal to bring 20 biosimilars to the U.S. market by 2030.
FDA approval expands patient access to therapies for ACCORD.
From prnewswire.com
Who's involved
- FDARegulatory agency that approved the drug.
- United States of AmericaMarket where the drug was commercially launched.
Keep exploring
The entities involved
Related events
- Ligand Pharmaceuticals received FDA approval for its drug Filspari and was listed on the Nasdaq stock exchange.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- A product was launched in the U.S. market following FDA involvement.
- Inventiva seeks FDA approval for lanifibranor in the U.S. market.
- The FDA recommended advancement for a new drug application submitted by a company.